Prosecution Insights
Last updated: October 02, 2026

Examiner: FAY, ZOHREH ALEMZADEH

Tech Center 1700 • Art Units: 1612 1616 1617 1621 1627 1629 1783

This examiner grants 52% of resolved cases

Performance Statistics

52.2%
Allow Rate
-12.8% vs TC avg
1,186
Total Applications
-6.2%
Interview Lift
1187
Avg Prosecution Days
Based on 1127 resolved cases, 2023–2026

Rejection Statute Breakdown

3.0%
§101 Eligibility
10.6%
§102 Novelty
51.8%
§103 Obviousness
20.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19189086 RISANKIZUMAB COMPOSITIONS Non-Final OA ABBVIE INC.
18011399 REDOX-RESPONSIVE NANOPARTICLE COMPOSITIONS FOR OCULAR DELIVERY OF THERAPEUTICS Final Rejection OHIO STATE INNOVATION FOUNDATION
17760990 HIGH DENSITY LIPOPROTEIN-LIKE NANOPARTICLES AS INDUCERS OF FERROPTOSIS IN CANCER Non-Final OA Northwestern University
18133784 COMPOSITIONS AND METHODS FOR LOWERING INTRACRANIAL PRESSURE Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
17849545 BIOMIMETIC POLYMERIC COMPOSITE FOR HEART VALVE REPAIR Non-Final OA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
18713218 COSMETIC WATER-IN-OIL EMULSION COMPRISING A SPECIFIC WATER-SOLUBLE UV SCREENING AGENT, A BASE, A VOLATILE OIL, A HYDROPHOBIC FILM-FORMING POLYMER, A POLYOXYALKYLENATED LINEAR POLYDIMETHYLMETHYLSILOXANE AND A VITAMIN B3 Non-Final OA L'OREAL
18281381 COSMETIC SKIN CARE COMPOSITION Final Rejection Conopco, Inc., d/b/a UNILEVER
18836055 CLEAR HAIR STYLING FORMULATION Non-Final OA Rohm and Haas Company
17909601 STABILIZATION OF COMPOUNDS AS CYCLODEXTRIN COMPLEXES Non-Final OA University of Pittsburgh - Of the Commonwealth System of Higher Education
18692074 MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE Non-Final OA AUSPEX PHARMACEUTICALS, INC.
17503581 CONJUGATES OF AUXIN ANALOGS Final Rejection Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
17763010 SEED COATING COMPOSITIONS Non-Final OA CORN PRODUCTS DEVELOPMENT, INC.
17796843 USE OF POLYETHER COMPOUND Non-Final OA Senju Pharmaceutical Co., Ltd.
17907953 NEW USE AND METHOD OF TREATMENT Non-Final OA HUNTER CAPITAL AB (PUBL)

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month